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3748ABSTRACT
Background. Carbapenemase-producing Enterobacteriaceae (CPE) can lead to life-
threatening outcomes with rapid spread of the carbapenemase gene in solid organ
transplantation (SOT) recipients because of limitations of available antibiotics. We
examined the characteristics and importance of CPE acquisition in SOT recipients with
large numbers of CPE isolates.
Methods. Between November 2015 and October 2016, 584 CPE isolates were found in
37 recipients and veriﬁed by carbapenemase gene multiplex polymerase chain reaction
(PCR). One hundred recipients with at least 2 negative results in carbapenemase PCR
for stool surveillance and no CPE isolates in clinical samples were retrospectively
included.
Results. Most CPE isolates were Klebsiella pneumoniae carbapenemase (KPC)-producing
K. pneumoniae (546, 93.5%). The most frequent transplantation organ was lung (43.3%),
and the most common sample with CPE isolates other than stool was respiratory tract
(22.6%). The median time between SOT and ﬁrst CPE acquisition was 7 days. All-cause
mortality was signiﬁcantly higher in recipients with CPE than in those without CPE
(24.3% vs 10.0%; P ¼ .03). In multivariate regression analysis, stool colonization of
vancomycin-resistant Enterococci and/or Clostridium difﬁcile during 30 days before SOT
(odds ratio [OR], 3.28; 95% CI, 1.24e8.68; P ¼ .02), lung transplantation (OR, 4.50;
95% CI, 1.19e17.03; P ¼ .03), and intensive care unit stay 2 weeks (OR, 6.21; 95% CI,
1.72e22.45; P ¼ .005) were associated with acquisition of CPE.
Conclusions. Early posttransplantation CPE acquisition may affect the clinical outcome
of SOT recipients. Careful screening for CPE during the early posttransplantation period
would be meaningful in recipients with risk factors.*Address correspondence to Sang Hoon Han, MD, PhD, Divi-
sion of Infectious Disease, Department of Internal Medicine,
Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-
gu, Seoul 06273, Republic of Korea. Tel: þ82-2-2019-3310,
Fax: þ82-2-3463-3882. E-mail: shhan74@yuhs.acINVASIVE infection with multidrug-resistant gram-negative bacteria (MDR-GNB) after solid organ
transplantation (SOT) is a consistent and growing global
problem that is associated with life-threatening detrimental
outcomes including graft dysfunction and high8
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or infection with carbapenem-resistant Enterobacteriaceae
(CRE), most commonly carbapenem-resistant Klebsiella
pneumoniae (KPN), in SOT recipients is recently emerging,
mainly in the general population of high CRE-endemic
regions [3e8]. Notably, carbapenemase-producing Entero-
bacteriaceae (CPE) might be more virulent than CRE that
do not produce the carbapenemase and may be clinically
and epidemiologically important because the carbapenem-
ase gene could easily spread to immunosuppressed SOT
recipients who are especially vulnerable to disseminated
infections through recipient-to-recipient, donor-to-recip-
ient, or hospital environment and/or health care worker-to-
recipient transmission of highly mobile genetic elements
[8e13]. In this respect, physicians have to comply with
several strict infection prevention and control measures to
control the CPE outbreak [10,14]. Another ominous impli-
cation for the spread of CPE is the lack of limited possi-
bilities for the selection of appropriately veriﬁed
antimicrobial agents against CPE [15e17].
After the isolation of CPE-producing K. pneumoniae
carbapenemase (KPC)-2 in kidney transplant recipients was
ﬁrst reported in New York in 2006 [18], the threat of CPE
acquisition as infection or colonization, especially of KPC-
producing Enterobacteriaceae, in SOT recipients has
continuously been increasing since 2011 [19e23]. However,
these reports were commonly case series with a small
number of SOT recipients with CPE infection (maximum
21) and limited numbers of CPE isolates [19e24]. There-
fore, we might not have sufﬁcient knowledge about risk
factors and the clinical impact of CPE acquisition on
outcome in SOT recipients. Because our hospitals have
experienced a great increase in CPE cases, we were able to
collect a variety of clinical data for hundreds of CPE isolates
in SOT recipients. This analysis aimed to evaluate the
clinical characteristics and effects of CPE acquisition in
SOT recipients through examination of a large number of
CPE isolates.METHODS
Study Design and Patient Collection
We retrieved all data from antibiotic susceptibility tests for
Enterobacteriaceae and polymerase chain reaction (PCR) for
carbapenemase genes from electronic medical records for 309
recipients aged at least 20 years who received SOT between
November 2015 and October 2016 at Yonsei University Health
System, Severance and Gangnam Severance Hospital, university-
afﬁliated tertiary care centers with a total of 3500 beds in Seoul,
South Korea. We conﬁned the Enterobacteriaceae family to the
genera of Citrobacter, Enterobacter, Escherichia, Klebsiella, Morga-
nella, Proteus, Providencia, Raoultella, and Serratia spp, which are
common human pathogens [12]. We excluded 12 recipients who
received retransplantation and/or had already taken immunosup-
pressive drugs before inductive immunosuppressive therapy for
SOT. Finally, after additional exclusion of 3 recipients with
carbapenemase-nonproducing CRE, 37 recipients who ever had
CPE in any clinical sample, including stool or rectal swab, duringhospital stay for SOT were selected as the group with CPE. We
included all 100 SOT recipients without CRE and CPE isolates,
deﬁned as 2 or more negative results in a PCR test for carbapen-
emase genes for stool surveillance and no CPE isolates in clinical
samples during hospital stay for SOT, as a control group to identify
the factors associated with CPE acquisition in SOT recipients and
to evaluate the effects of CPE on clinical outcomes. During the
study period, active surveillance for CPE in stool or rectal swab
using a carbapenemase gene PCR test to detect stool CPE carriers
and contact precaution control measures were implemented for
patients who had CRE and/or CPE clinical isolates, were admitted
to the intensive care unit (ICU) before/after SOT, or had suspected
history of contact with other patients infected or colonized by CPE
[10,14]. This study was approved by the local Ethics Committee of
the Institutional Review Board with waiver of informed consent.
Isolation of Carbapenemase-Producing Enterobacteriaceae
and Veriﬁcation of Carbapenemase Type
We used the MALDI Biotyper system (Bruker Co, Ltd, Billerica,
Mass, United States) to identify species of Enterobacteriaceae from
positive cultures in clinical sample. The antimicrobial susceptibility
tests for Enterobacteriaceae were performed according to the
breakpoints and standard guidelines from the Clinical and
Laboratory Standards Institute (CLSI) in M100-S25 [25]. If the
Enterobacteriaceae isolate was resistant to meropenem and ertape-
nem, we performed the modiﬁed Hodge test (MHT) for
ﬁrst-isolated CRE in each recipient in conformity with CLSI stan-
dards and designated it as CPE when an isolate with positive MHT
had any carbapenemase gene in the multiplex PCR test [25,26].
When each recipient had repeatedly isolated CRE for least 3 days
in an identical sample, CPE was directly conﬁrmed through the
carbapenemase gene PCR test without MHT. The carbapenemase
gene PCR test was performed using a PANA RealTyper CRE Kit
according to the manufacturer’s instructions (PANAGENE Inc,
Daejeon, Korea) [27]. This multiplex real-time PCR kit can detect 9
kinds of carbapenemase gene including class A carbapenemase of
KPC and Guiana extended-spectrum, class B metallo-b-lactamases
(MBL) carbapenemase of imipenemase-type carbapenemase, New
Delhi MBL (NDM) and Verona integrin-encoded MBL (VIM),
and class D OXA carbapenemases (OXA-23, OXA-48, OXA-58,
and ISAba1-OXA-51) using peptide nucleic acid ﬂuorescent probe
and melting curve analysis [28e31]. Brieﬂy, 4 probe dyes, FAM,
HEX, ROX, and Cy5, were used, and the real-time PCR was per-
formed with the CFX96 Real-Time PCR Detection System (Bio-
Rad Laboratories, Inc, Calif, United States) with the following
cycling conditions: 2 minutes at 50C and 15 minutes at 95C,
followed by 45 cycles of 15 seconds at 95C, 45 seconds at 58C, and
15 seconds at 72C. Afterward, additional reaction for 5 minutes at
95C, 5 minutes at 35C, and 5 seconds at 35C to 80C was per-
formed for melting curve analysis. The unique melting temperature
value for each of the 4 peptide nucleic acid ﬂuorescent probes can
identify the presence of each carbapenemase gene [27,30].
Collection of Clinical Information
Together with the usual information for SOT, we collected data for
pretransplantation sensitization to HLAs. These include the
complement-dependent cytotoxicity-lymphocyte cross-match test
for T cells (time long and antihuman globulin phages) and B cells
(warm phages) as well as the Luminex panel-reactive antibody
(PRA) screen and identiﬁcation of multiple class I and II HLAs by
bead-based immunoassay using LABScreen Mixed assay and
Table 1. Characteristics of 37 Solid Organ Transplantation
Recipients With Carbapenemase-Producing Enterobacteriaceae
and 584 Carbapenemase-Producing Enterobacteriaceae
Isolates
Characteristics
Time between SOT and ﬁrst isolation of
CPE, median (range), d
7 (19 to 230)*
Time between date of admission to hospital
for SOT and ﬁrst isolation of CPE, median
(range), d
29 (2 to 236)
Features of CPE isolation in 37 recipients,
No. (%)
Clinical samples excluding stool/rectal
swab (no stool carrier)†
2 (5.4)
Clinical samples and stool/rectal swab 24 (64.9)
Stool/rectal swab excluding other clinical
samples‡
11 (29.7)
Results by CPE acquisition in 37 recipients,
No. (%)
Apparent infection§ 11 (29.7)
Bacteremia 6 (16.2)
Pneumoniak with bacteremia 2 (5.4)
Pneumoniak without bacteremia 5 (13.5)
Colonization 26 (70.3)
Species (n ¼ 584), No. (%)
Klebsiella pneumonia 546 (93.5)
Escherichia coli 17 (3.0)
Enterobacter aerogenes 11 (1.9)
Raoultella ornithinolytica 3 (0.5)
Klebsiella oxytoca 2 (0.3)
Citrobacter amalonaticus 2 (0.3)
Citrobacter freundii 2 (0.3)
Enterobacter cloacae 1 (0.2)
Type of carbapenemase (n ¼ 584), No. (%)
KPC 580 (99.3)
NDM 4 (0.7)
ESBL production among CPE isolates
cultured in samples except stool/
rectal swab (n ¼ 216), No. (%)
Yes 4 (1.9)
No 212 (98.1)
Isolated sites (n ¼ 584), No. (%)
Blood 19 (3.3)
Respiratory tract 132 (22.6)
Upper¶ 96 (16.4)
Lower** 36 (6.2)
Urine 25 (4.3)
Peritoneal ﬂuid from indwelling catheter 3 (0.5)
Pleural ﬂuid from indwelling catheter 9 (1.5)
Bile from indwelling catheter 3 (0.5)
Wound 21 (3.6)
Cervix 4 (0.7)
Stool/rectal swab 368 (63.0)
Changing pattern of MIC for amikacin in 37
recipients, No. (%)
Not changed 12 (32.4)
Increased 9 (24.3)
Table 1. (continued)
Characteristics
All resistant 1 (2.7)
Not evaluated†† 15 (40.5)
Abbreviations: CPE, carbapenemase-producing Enterobacteriaceae; ESBL,
extended-spectrum b-lactamase; KPC, Klebsiella pneumonia carbapenemase;
MIC, minimal inhibitory concentration; NDM, New Delhi metallo-beta-lactamase;
SOT, solid organ transplantation.
*A negative value means that CPE was isolated before transplantation.
†No carbapenemase gene was detected in PCR in  2 samples of stool or
rectal swab.
‡CPE was not isolated in tests of all cultures of clinical samples (excluding
stool or rectal swab) performed to diagnose infection or monitor colonization
according to the physician’s decision.
§Apparent infection was strictly conﬁned to only bacteremia and pneumonia.
kPneumonia was strictly deﬁned as CPE isolated from a sample from the
lower respiratory tract with other clinical/laboratorial/radiological evidence.
¶Includes samples from oral cavity, throat, sputum, and nasopharyngeal or
oropharyngeal suction as well as suction from endobronchial tube.
**Includes samples from bronchial washing and bronchoalveolar lavage
through bronchoscopy.
††Cases in which CPE was isolated once and/or in only stool/rectal swab.
3750 LEE, HAN, YONG ET ALLABScreen PRA Class I/II assay, respectively (One Lambda, Inc,
Canoga Park, Calif, United States) [32e34]. The percentage score of
the PRA identiﬁcation test was calculated by the following equa-
tion: (no. of positive bead reaction/total no. of beads)  100 [34].
When considered clinically necessary by the physician, further
evaluation including culture, PCR of van A and/or van B, and
enzyme-linked immunoassay of toxin A and/or B for vancomycin-
resistant Enterococci (VRE) or Clostridium difﬁcile in stool was
performed for diagnosis of C difﬁcile infection or for infection
control measurement of VRE.
Deﬁnitions
We used the phenotype-based deﬁnition based on antimicrobial
susceptibility patterns to identify CRE [26]. We considered an
isolate as CRE if it was resistant to meropenem with minimal
inhibitory concentration (MIC) 4 mg/mL and to ertapenem with
MIC 2 mg/mL according to the breakpoints of CLSI M100-S25
[25,26]. CPE was deﬁned as an isolate among CRE with any
carbapenemase gene in PCR [26]. We considered the patient a C
difﬁcile stool carrier if C difﬁcile was isolated in loose stool irre-
spective of production of toxin A or B. The VRE isolates were
veriﬁed by PCR test for vanA or vanB. We strictly conﬁned
apparent infection by CPE to bacteremia and/or pneumonia to
avoid any subjective decisions. CPE bacteremia was deﬁned as CPE
isolation in at least 1 pair of samples from peripheral blood of a
patient with symptoms and signs of systemic infection [13]. Pneu-
monia was strictly deﬁned as CPE isolation in the lower respiratory
tract, including bronchial washing or bronchoalveolar lavage,
together with lung parenchymal inﬁltration and signs of systemic
infection [35]. Acute rejection was deﬁned as a transplantation
organespeciﬁc classiﬁcation [36e38]. Cytomegalovirus reactivation
was deﬁned as asymptomatic viremia regardless of viral titer, tissue-
invasive disease, or cytomegalovirus syndrome [39]. We deﬁned the
follow-up endpoint as the discharge date from hospital stay for SOT
for recipients who were alive or as the date of death for recipients
who died.
Fig 1. Time between solid organ transplantation surgery and ﬁrst isolation of carbapenemase-producing Enterobacteriaceae (CPE). A
negative value means that CPE was isolated before transplantation.
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Data were expressed as number (percent) or median (range or
interquartile range [IQR]). To compare continuous variables
between 2 groups, we used the independent t test and Mann-
Whitney test for normal and non-normal distributions, respec-
tively. Categorical variables were compared between 2 groups by
c2 test or Fisher exact test. We performed multivariate logistic
regression analysis to identify independent clinical factors asso-
ciated with CPE acquisition in SOT recipients with inclusion of all
nominal variables that showed statistical signiﬁcance with
P value .05 in univariate analysis. Survival analysis was per-
formed using a log-rank test. All P values were 2-tailed, and a
P value .05 was considered statistically signiﬁcant. We used SPSS
V23 (IBM Corp, Armonk, NY, United States) and GraphPad
Prism V6 (GraphPad Software, Inc, La Jolla, Calif, United States)
software for statistical analyses and graphs.RESULTS
Characteristics of Carbapenemase-Producing
Enterobacteriaceae Isolates
The great majority of total CPE isolates were KPC-
producing and extended-spectrum beta-lactamase (ESBL)-
nonproducing KPN (546 of 584, 93.5%). Four isolates
producing NDM were Citrobacter amalonaticus, Raoultella
ornithinolytica, Klebsiella oxytoca, and Enterobacter cloacae.
CPE was most commonly isolated in samples from respi-
ratory tract (132 of 584, 22.6%) irrespective of the trans-
plantation organ when we did not consider CPE isolated in
stool or rectal swab (Table 1). The CPE isolation site did
not show a distinct association with transplantation organ.
The percentage of respiratory tract isolates among total
CPE isolation sites in recipients of lung (n ¼ 16) and liver
(n ¼ 14) transplants was 76.8% (116 of 151) and 88.5% (46
of 52), respectively. Of the total 216 CPE isolates in samples
except stool or rectal swab, 151 (70.0%) were identiﬁed in
lung transplant recipients. Two different CPE species, KPC-
producing KPN and KPC-producing Escherichia coli, wereisolated concurrently in the same stool and/or rectal swab
sample of 4 SOT recipients. The median time between
transplantation and ﬁrst isolation of CPE was 7 days, and
the longest interval was 230 days. Three recipients showed
the ﬁrst CPE isolate 1, 5, and 19 days before transplantation
(Table 1, Fig 1).
Only 20 (9.3%) among 216 CPE isolates were susceptible
to tigecycline. The resistance rates for gentamicin (87.5%),
levoﬂoxacin (95.8%), and trimethoprim and/or sulfameth-
oxazole (93.5%) were very high. However, susceptibility to
amikacin was maintained in the majority of isolates (87.5%)
(Table 2). Nevertheless, 9 of 37 (24.3%) recipients had
increased MIC values for amikacin in repeatedly isolated
CPE (Table 1).
Characteristics of SOT Recipients With Carbapenemase-
Producing Enterobacteriaceae Isolates
Transplant recipients who did not have CPE isolates in stool
were in the minority (5.4%). CPE was isolated in both
clinical samples and stool and/or rectal swab in 24 of 37
(64.9%) recipients, and 11 (29.7%) recipients had CPE
isolates in only stool or rectal swab, but not other clinical
samples (Table 1). Bacteremia by CPE occurred in 6
(16.2%) recipients (5 with lung transplant and 1 with liver
transplant). Fifty percent of CPE-bacteremia recipients had
died at 71, 110, and 176 days after transplantation and at 32,
53, and 164 days after the ﬁrst CPE bacteremia.
Comparison of Characteristics Between SOT Recipients With
and Without Carbapenemase-Producing Enterobacteriaceae
Isolates
The frequency of recipients who received lung trans-
plantation was signiﬁcantly higher in the group with CPE
compared with SOT recipients without CPE acquisition
(43.3% vs 10.0%; P ¼ .001). Age, type of donor, type of
induction immunosuppressive drugs, and degree of
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3752 LEE, HAN, YONG ET ALpretransplantation sensitization did not show signiﬁcant
differences between the 2 groups (Table 3).
We compared prior isolation of another bacteria, anti-
biotic use, and duration of hospital stay as well as ICU stay
during the period between 30 days before transplantation
and ﬁrst CPE acquisition in the group with CPE or the
endpoint of follow-up in the group without CPE. Prior
isolation of carbapenem-sensitive Enterobacteriaceae,
irrespective of whether it produced ESBL, was more
frequent in the group with CPE (45.9% vs 22.0%; P ¼ .006).
The number of recipients who received carbapenem treat-
ment was signiﬁcantly larger in the group with CPE (54.1%
vs 30.0%; P ¼ .009), and the duration of carbapenem use
was signiﬁcantly longer in the group with CPE (median
[IQR], 2 [0e8] vs 0 [0e4] days; P ¼ .02). The total hospital
days before transplantation were similar between 2 groups,
but duration of ICU stay was signiﬁcantly longer in the
group with CPE (median [IQR], 13 [3e29] vs 3 [2e7] days;
P < .001) (Table 3). All-cause mortality was signiﬁcantly
higher in recipients with CPE acquisition (24.3% vs. 10.0%;
P ¼ .025) (Fig 2).
Independent Factors Associated With CPE Acquisition
We used the median value of 2 weeks in the group with CPE
as the cutoff duration for longer ICU stay for logistic
analysis. The multivariate regression model revealed that
VRE or C difﬁcile colonization in stool (OR, 3.3; 95% CI,
1.2e8.7; P ¼ .02), longer ICU stay  2 weeks (OR, 6.2; 95%
CI, 1.7e22.5; P ¼ .005) during the 30 days before SOT, and
lung transplantation (OR, 4.5; 95% CI, 1.2e17.0; P ¼ .03)
were independently associated with CPE acquisition
(Table 4).
DISCUSSION
Compared with previous reports, this study included the
largest number of CPE isolates, nearly all KPC-producing
ESBL-nonproducing KPN, identiﬁed in SOT recipients.
We collected and analyzed clinical and microbiological data
for 584 CPE isolates from various sites including stool and/
or rectal swab. Our study showed that CPE acquisition was
associated with high all-cause mortality after SOT, as
reported for other MDR gram-positive and -negative
bacteria [1,2,13,40]. CPE acquisition occurred at the
immediate early period after transplantation, with a median
time of 1 week. However, more profound induction of
immunosuppression according to pretransplantation sensi-
tization, which could affect early immune status, did not
have a signiﬁcant association with CPE acquisition. These
ﬁndings are similar to the universal hallmark of health
careeassociated MDR bacterial infections occurring within
1 month after SOT [1,2]. Pretransplantation CPE acquisi-
tion might occur more frequently if the length of admission
before transplantation is longer.
The most vulnerable population for CPE acquisition in
our study was lung transplant recipients with a longer ICU
stay before transplantation. A history of ICU admission and
Table 3. Comparison of Clinical Characteristics of Solid Organ Transplantation Recipients With or Without Acquisition of
Carbapenemase-Producing Enterobacteriaceae
Characteristics
CPE
P Value
Positive
(N ¼ 37)
Negative
(N ¼ 100)
Age, mean (SD), y 56.0 (10.2) 55.0 (10.8) .65*
Sex, male, No. (%) 22 (59.5) 71 (71.0) .22†
Transplantation organ, No. (%) .001‡
Kidney 4 (10.8) 17 (17.0)
Liver 14 (37.8) 54 (54.0)
Lung 16 (43.3) 10 (10.0)
Heart 3 (8.1) 14 (14.0)
Pancreas 0 (0) 5 (5.0)
Type of donor, No. (%) .12†
Living 11 (29.7) 26 (26.0)
Deceased 26 (70.3) 55 (55.0)
Induction immunosuppressive drug, No. (%)
Antithymocyte globulin 1 (2.7) 8 (8.0) .44‡
Basiliximab 3 (8.1) 22 (22.0) .08†
Pretransplantation sensitization
HLA mismatch, No. (%)
T lymphocyte 1 (2.7) 8 (8.0) .44‡
B lymphocyte 2 (5.4) 7 (7.0) >.99‡
Panel-reactive antibody
Screen, anti-HLA antibody, positive, No. (%)
Class I 11 (29.7) 37 (37.0) .43†
Class II 8 (21.6) 22 (22.0) >.99†
Identiﬁcation, median (IQR), %
Class I 2 (0e31) 3 (0e29) .82§
Class II 2 (0e40) 0 (0e29) .20§
Prior isolation of carbapenem-sensitive Enterobacteriaceae*,
EBSL-nonproducing or ESBL-producing, No. (%)
17 (45.9) 22 (22.0) .006†
Only ESBL-producing 8 (21.6) 11 (11.0) .11†
Only ESBL-nonproducing 4 (10.8) 9 (9.0) .75‡
Use of carbapenemsk, No. (%) 20 (54.1) 30 (30.0) .009†
Total duration of carbapenem usek, median (IQR), d 2 (0e8) 0 (0e4) .02§
Hospital stay before SOT¶, median (IQR), d 10 (4e26) 8 (2e14) .14§
Total duration of ICU stayk, median (IQR), d 13 (3e29) 3 (2e7) <.001‡
VRE or C difﬁcile isolation in stoolk, yes, No. (%) 16 (43.2) 16 (16.0) .001†
Acute rejection, yes, No. (%) 2 (5.4) 17 (17.0) .10†
CMV reactivation, yes, No. (%) 25 (67.6) 34 (34.0) .001†
Abbreviations: CMV, cytomegalovirus; CPE, carbapenemase-producing Enterobacteriaceae; ESBL, extended-spectrum beta-lactamase; ICU, intensive care unit;
IQR, interquartile range; SOT, solid organ transplantation; VRE, vancomycin-resistant enterococci.
*Independent sample t test.
†Pearson c2 test.
‡Fisher exact test.
§Mann-Whitney test.
kFor the period between 30 days before transplantation and endpoint of follow-up in recipients without CPE and between 30 days transplantation and ﬁrst CPE
acquisition in recipients with CPE.
¶From time of admission for SOT.
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MDR pathogens, even in nontransplant patients [1,17,35].
In our center, lung transplant recipients usually received
longer ICU care before and after transplantation compared
with kidney and liver transplant recipients because of
mechanical ventilation or percutaneous cardiopulmonary
support treatment. Nevertheless, lung transplantation itself
was an independent factor of CPE acquisition.
An interesting ﬁnding was that previous stool coloniza-
tion of VRE and/or C difﬁcile was independently associated
with CPE acquisition. This suggests that alteration ofgastrointestinal ﬂora caused by various factors including
prolonged ICU stay or broad-spectrum antibiotic treatment
might intensify the effect of colonization with other easily
transmissible and highly environment-resistant enteric
bacteria on the probability of CPE acquisition. Further
microbiological or molecular studies of gut microbiota in
patients with CPE and MDR-GNB will be helpful to un-
derstand this feature. It might have important clinical
meaning for controlling the further spread of CPE, a new
detrimental MDR pathogen, into the SOT recipient popu-
lation that is especially vulnerable to invasive CPE infection
Table 4. Multivariate Logistic Regression Analysis to Identify
Independent Clinical Factors Associated With Carbapenemase-
Producing Enterobacteriaceae Acquisition in Solid Organ
Transplantation Recipients
Variables OR 95% CI P Value
Transplantation organ
Lung 4.50 1.19e17.03 .03
Liver 2.16 0.67e7.00 .20
Prior isolation of carbapenem-
sensitive Enterobacteriaceae,
ESBL-nonproducing or
ESBL-producing*, yes
1.82 0.64e5.14 .26
VRE or C difﬁcile colonization in
stool*, yes
3.28 1.24e8.68 .02
Previous use of carbapenems*, yes 1.50 0.47e4.84 .495
Longer ICU stay*, >2 wk 6.21 1.72e22.45 .005
Abbreviations: CI, conﬁdence interval; ESBL, extended-spectrum b-
lactamase; ICU, intensive care unit; OR, odds ratio; VRE, vancomycin-resistant
enterococci.
*At 30 days before transplantation.
Fig 2. KaplaneMeier survival curve for solid organ transplanta-
tion recipients with or without acquisition of carbapenemase-
producing Enterobacteriaceae. *Log-rank test. Abbreviations:
CPE, carbapenemase-producing Enterobacteriaceae.
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antimicrobial agents such as polymyxin E to treat invasive
CPE infection could bring additional morbidity and
mortality caused by drug toxicity, especially dysfunction of
renal allografts due to polymyxin E-induced nephrotoxicity.
CPE might have nearly identical epidemiologic and clinical
features to VRE, namely prior stool colonization in most
cases and development of life-threatening invasive infection
as well as a long time for eradication from stool.
Even though we strictly applied several infection control
measures including the most important one of active sur-
veillance through stool and/or rectal swab examination in
patients with high risk, those admitted to ICU, and those with
contact isolation, effective elimination of CPE was extremely
difﬁcult. Repeated admission to the transplantation unit or
ward can increase the risk of CPE spread in the relatively
homogenous SOT recipient population.We also experienced
CPE isolation as stool colonization in most cases in a general
ward with restricted admission for SOT recipients.
Our data showing the coexistence of KPC-producing
KPN and KPC-producing E coli in stool raise concern
about interspecies spread of carbapenemase genes between
KPN and E coli in a single recipient through mobile genetic
cassettes. These 2 bacteria are common pathogens of health
careeassociated infection together with glucose nonferment
GNB of Pseudomonas aeruginosa and Acinetobacter
baumannii of majors for MDR-GNB. We found that KPN
and E coli could coexist in the colon at a relatively high
frequency, especially in SOT recipients with life-long
immunosuppressive treatment, unlike with glucose non-
fermenting GNB.
The major limitation of the study was that susceptibility
tests for polymyxin E were not routinely performed; there-
fore, we could not obtain the rate of resistance to polymyxin
E, which is currently the most potent antibiotic against CPE.
In addition, our recipients included a small number of heart
and lung dual transplantation recipients and did not include
intestinal transplantation recipients, populations that aresusceptible to health careeassociated MDR-GNB infection
[1]. We were also unable to continuously perform strict
surveillancewitha regularmonitoring schedule inall recipients
although almost all recipients with risk factors received PCR
tests for carbapenemase genes with stool samples at a 1-week
interval. These data did not include microbiological molecu-
lar analyses including subtype of KPC/NDM, pulsed gel elec-
trophoresis and/or multilocus sequence typing, and detailed
analyses of the structure of carbapenemase genes; therefore,
we cannot provide any information on whether these CPE
isolates originated from single or multiple clones. However,
this study has the following unique strengths: (1) imple-
mentation of the strictest deﬁnitions for CRE and apparent
infection and (2) the ﬁrst detailed analysis of large data for all
CPE isolates including stool colonization in a homogeneous
SOT recipient population.
CONCLUSIONS
Our analyses revealed that the acquisition of KPC-
producing KPN in SOT recipients occurred in the early
posttransplantation period and was associated with lung
transplantation, prior VRE or C difﬁcile stool colonization,
and longer ICU stay. The implementation of active control
measures should be applied to SOT recipients, especially
with these risk factors, to decrease the mortality caused by
CPE acquisition itself and the morbidities related to inva-
sive CPE infection.
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